Review
Neurosciences
Miriam Olivola, Nicola Bassetti, Serena Parente, Vincenzo Arienti, Serena Chiara Civardi, Pietro Alessandro Topa, Natascia Brondino
Summary: This systematic review explores the efficacy of lurasidone and cariprazine in improving cognition in schizophrenia patients. The results show that lurasidone has better cognitive performance in both animal and human studies, while cariprazine also has a good effect on improving cognitive functions in both animal and human studies. The cognitive effect of lurasidone may be explained by its potent antagonism at the 5-HT7 receptors combined with partial agonism at the 5-HT1A receptors, and the cognitive efficacy of cariprazine may be due to its high affinity for D3 receptors.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Psychiatry
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode, Anita Kablinger
Summary: Antipsychotic medications are used for various psychiatric disorders, but their side effects often limit their short-term and long-term use. Newer antipsychotic agents like brexpiprazole, cariprazine, and lumateperone are promising in treating neuropsychiatric conditions, but head-to-head comparisons with other antipsychotics are needed to determine their effectiveness.
WORLD JOURNAL OF PSYCHIATRY
(2021)
Article
Psychiatry
Emanuela Dyrmishi, Marco De Pieri, Marco Ferrari, Rafael Traber, Matteo Preve, Luca De Peri, Emilio Bolla
Summary: The cases of three outpatients with bipolar I disorder and schizoaffective disorder, who had low adherence to treatment, were treated with cariprazine as a monotherapy on a two-times a week schedule. After four weeks of treatment, all three patients showed response and remission, and this result was sustained for several months. The long half-lives of cariprazine and its active metabolites seem to provide effective treatment with a two-times a week administration.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Pharmacology & Pharmacy
Jessica Greger, Traci Aladeen, Emily Lewandowski, Rachael Wojcik, Erica Westphal, Michelle Rainka, Horacio Capote
Summary: Newer second-generation antipsychotics (SGAs) such as brexpiprazole and iloperidone were found to cause significant weight gain in patients, while older SGA olanzapine had more unfavorable metabolic characteristics. Monitoring weight and metabolic parameters remains crucial for patients treated with SGAs.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Angaja Phalguni, Rachael McCool, Hannah Wood, Alice Sanderson, Gustaf Rydevik, Brooke Franklin, Daniel James
Summary: A systematic review was conducted to compare the efficacy and safety of lurasidone, brexpiprazole, and cariprazine in adult patients with schizophrenia. Lurasidone at a dose of 160 mg showed the best results in terms of improvement in PANSS and CGI-S scores at 6 weeks.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kouji Fukuyama, Eishi Motomura, Motohiro Okada
Summary: This study investigates the effects of Brexpiprazole on protein expression, intracellular signaling, and cAMP levels in astrocytes and rat hypothalamus. The results suggest that Brexpiprazole has complex pharmacological features, with partial agonistic action on 5-HT1AR and inverse agonist-like action on 5-HT7R. The suppressive effects of Brexpiprazole on 5-HT7R play an important role in its antidepressive and mood-stabilizing actions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Leire Zazu, Teresa Morera-Herreras, Montserrat Garcia, Carmelo Aguirre, Unax Lertxundi
Summary: This study aimed to investigate the association between cariprazine, brexpiprazole, and impulse control symptoms (ICS), revealing a higher number of reported ICS cases for these drugs in EudraVigilance. However, further well-designed observational analytical studies are needed to confirm these results and establish a definitive safety signal.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Biology
Rachel E. Hardy, Injae Chung, Yizhou Yu, Samantha H. Y. Loh, Nobuhiro Morone, Clement Soleilhavoup, Marco Travaglio, Riccardo Serreli, Lia Panman, Kelvin Cain, Judy Hirst, Luis M. Martins, Marion MacFarlane, Kenneth R. Pryde
Summary: Antipsychotic drugs, including the newer generation ones, can induce mitochondrial toxicity that leads to movement disorders. It is important to understand the underlying mechanisms to minimize these adverse effects.
Review
Chemistry, Medicinal
Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanabe
Summary: This review provides a comprehensive overview of the drug design, development, and therapy of lurasidone for schizophrenia treatment. Lurasidone has specific effects on different receptors and has been found to be effective in improving symptoms and preventing relapse in patients with schizophrenia. It also has minimal metabolic side effects and improves cognitive and functional performance.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Clinical Neurology
Thomas Aubel
Summary: Schizophrenia is a chronic mental disorder characterized by positive, negative, and cognitive symptoms, requiring long-term treatment. Pharmacologic therapy, including the use of antipsychotics like cariprazine, has been shown to be effective in managing the symptoms of schizophrenia. Multiple trials have demonstrated the efficacy of cariprazine in treating schizophrenia, making it a valuable option for patients with inadequate response to previous treatments.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Psychiatry
Elena Ivanova, Desislava Maslinkova, Nadia Polnareva, Vihra Milanova
Summary: This study reports two cases of young patients with predominantly negative symptoms during treatment with cariprazine. The results show that after 18 months of treatment, cariprazine significantly improved negative symptoms, global functioning, and clinical impression. Therefore, cariprazine may be a successful alternative for young schizophrenic patients with a predominance of negative symptoms.
FRONTIERS IN PSYCHIATRY
(2023)
Review
Chemistry, Medicinal
Mauricio Tohen
Summary: Depressive episodes are common in bipolar disorder and often lead to poor functional outcomes. Limited treatments are approved for bipolar depression, but recent approval of cariprazine, a dopamine antagonist/partial agonist, shows it to be effective and well-tolerated.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Clinical Neurology
Jose M. Montes, Paloma Montes, Daniel Hernandez-Huerta
Summary: Cariprazine, as a new-generation antipsychotic with partial agonism of dopamine receptors, may have unique advantages for patients with predominant negative symptoms. In acute exacerbations of schizophrenia, treatment with Cariprazine can achieve good efficacy, especially on negative and cognitive symptoms.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Psychiatry
Jose Rodriguez Cruz, Johan Sahlsten Scholin, Stephan Hjorth
Summary: A 30-year-old male diagnosed with schizophrenia and a long history of drug abuse showed significant improvement in symptoms, particularly in cognition and negative symptoms, after switching from Haloperidol to Cariprazine. Subsequent adjustments in antipsychotic dosages and adjunct medications led to more stable alleviation of symptoms, including improved personal and social capabilities. Joint treatment with Cariprazine in combination with Quetiapine appeared to enhance the patient's cognitive functioning and possibly reduce susceptibility to substance abuse.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Pharmacology & Pharmacy
Marco De Pieri, Marco Ferrari, Franca Marino, Rafael Traber, Emilio Bolla, Marco Cosentino
Summary: This pilot study found a correlation between SNPs in the DRD2 gene and response to Cariprazine treatment, suggesting the potential for new tools to predict and optimize treatment response.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Psychology, Developmental
Isabel Valli, Elena De la Serna, Alex G. Segura, Jose C. Pariente, Angels Calvet-Mirabent, Roger Borras, Daniel Ilzarbe, Dolores Moreno, Nuria Martin-Martinez, Inmaculada Baeza, Mireia Rosa-Justicia, Clemente Garcia-Rizo, Covadonga M. Diaz-Caneja, Nicolas A. Crossley, Allan H. Young, Eduard Vieta, Sergi Mas, Josefina Castro-Fornieles, Gisela Sugranyes
Summary: This study examined cognitive function and its clinical, genetic, and brain imaging correlates in youth at family risk for schizophrenia (SZ) and bipolar disorder (BP). Participants were grouped into intact, intermediate, and impaired clusters based on cognitive performance. The impaired cluster showed lower total brain surface area, particularly in the frontal and temporal cortices, and had poorer psychosocial functioning and worse PRS-COG compared to the other clusters and controls.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)
Article
Psychology, Clinical
Alex G. Segura, Gisela Mezquida, Albert Martinez-Pinteno, Patricia Gasso, Natalia Rodriguez, Lucia Moreno-Izco, Silvia Amoretti, Miquel Bioque, Antonio Lobo, Ana Gonzalez-Pinto, Alicia Garcia-Alcon, Alexandra Roldan-Bejarano, Eduard Vieta, Elena de la Serna, Alba Toll, Manuel J. Cuesta, Sergi Mas, Miquel Bernardo
Summary: Early intervention is crucial for preventing the progression of psychotic disorders. This study found that genetic susceptibility related to cognitive performance is associated with an increased risk of first-episode psychosis (FEP) and its clinical and cognitive progression. Additionally, genetic susceptibility for depression is associated with a worsening trajectory of executive function and general cognitive status.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Clinical Neurology
Giovanna Fico, Ulker Isayeva, Michele De Prisco, Vincenzo Oliva, Brisa Sole, Laura Montejo, Iria Grande, Nestor Arbelo, Marta Gomez-Ramiro, Luis Pintor, Bernardo Carpiniello, Mirko Manchia, Eduard Vieta, Andrea Murru
Summary: This systematic review and meta-analysis investigates the repurposing of psychotropic drugs in the treatment of COVID-19. The study finds that antidepressants do not significantly affect the risk and mortality of COVID-19, while fluvoxamine may have potential in reducing mortality risk. Antipsychotics may increase the risk of severe COVID-19 and mortality, but their use in psychiatric patients should be evaluated on a case-by-case basis.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Marco Solmi, Giovanni Croatto, Giada Piva, Stella Rosson, Paolo Fusar-Poli, Jose M. Rubio, Andre F. Carvalho, Eduard Vieta, Celso Arango, Nicole R. DeTore, Elizabeth S. Eberlin, Kim T. Mueser, Christoph U. Correll
Summary: Psychosocial interventions play an important role in schizophrenia and early psychosis. However, the literature on this topic is heterogeneous and contradictory. This umbrella review summarizes the findings from multiple meta-analyses comparing the effectiveness of different psychosocial interventions with standard treatment or other active interventions. The results suggest that early intervention services and cognitive behavioral therapy have significant effects on symptom reduction and functional improvement in early psychosis. For schizophrenia patients, cognitive behavioral therapy, psychoeducation, and any family interventions show positive effects on symptom reduction, relapse prevention, and functional improvement.
MOLECULAR PSYCHIATRY
(2023)
Article
Clinical Neurology
Alexandra J. M. Beunders, Federica Klaus, Almar A. L. Kok, Sigfried N. T. M. Schouws, Ralph W. Kupka, Hilary P. Blumberg, Farren Briggs, Lisa T. Eyler, Brent P. Forester, Orestes Forlenza, Ariel Gildengers, Esther Jimenez, Benoit H. Mulsant, Regan E. Patrick, Soham Rej, Martha Sajatovic, Kaylee Sarna, Ashley Sutherland, Joy Yala, Eduard Vieta, Luca M. Villa, Nicole C. M. Korten, Annemieke Dols
Summary: This study compared bipolar I disorder (BD-I) and bipolar II disorder (BD-II) in a large, global sample and found no significant differences between the two in terms of general functioning, cognition, and somatic burden. These findings suggest that the distinction between BD-I and BD-II may not be applicable to geriatric bipolar disorder patients.
Article
Clinical Neurology
Ana M. Sanchez-Torres, Silvia Amoretti, Monica Enguita-German, Gisela Mezquida, Lucia Moreno-Izco, Rocio Panadero-Gomez, Lide Rementeria, Alba Toll, Roberto Rodriguez-Jimenez, Alexandra Roldan, Edith Pomarol-Clotet, Angela Ibanez, Judith Usall, Fernando Contreras, Eduard Vieta, Jose M. Lopez-Ilundain, Jessica Merchan-Naranjo, Ana Gonzalez-Pinto, Esther Berrocoso, Miguel Bernardo, Manuel J. Cuesta
Summary: This study aimed to investigate the relationship between relapse, cognitive function, and cognitive reserve in schizophrenia patients. The results showed that higher personal cognitive reserve mitigated the negative effects of relapse on attention performance, while higher cognitive reserve (both personal and familial) improved processing speed and visual memory in patients who did not relapse. These findings provide evidence for the protective effect of cognitive reserve over the course of the illness.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti
Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Cristina Saiz-Masvidal, Fernando Contreras, Carles Soriano-Mas, Gisela Mezquida, Covadonga M. Diaz-Caneja, Eduard Vieta, Silvia Amoretti, Antonio Lobo, Ana Gonzalez-Pinto, Joost Janssen, Maria Sague-Vilavella, Josefina Castro-Fornieles, Daniel Berge, Miquel Bioque, Noemi G. Lois, Mara Parellada, Miguel Bernardo
Summary: The study investigates the relationship between structural brain alterations and clinical improvement in first-episode psychosis (FEP). Using structural covariance analysis, the researchers found increased correlation in brain regions involved in multisensory signal processing and bodily self-consciousness in the group that showed clinical improvement.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2023)
Review
Genetics & Heredity
Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, Chiara Fabbri, Alessandro Serretti
Summary: Nonpharmacological treatments for depression show effectiveness and tolerability in certain patients with diverse response. Genetic variables associated with treatment efficacy need to be examined to assist treatment selection. Most studies using candidate gene approach yielded poorly replicated findings due to small sample sizes, while a few methylome-wide and genome-wide association studies (GWASs) provided interesting results with the use of polygenic risk scores in small samples of electroconvulsive therapy (ECT) and cognitive-behavioral therapy. Further GWAS with larger sample sizes, such as the gen-ECT-ic consortium, can enhance our understanding of the genetic factors underlying treatment response in nonpharmacological therapies for depression.
PSYCHIATRIC GENETICS
(2023)
Article
Psychiatry
Norma Verdolini, Silvia Alonso-Lana, Pilar Salgado-Pineda, Salvador Sarro, Raymond Salvador, Teresa Maristany, Jose M. Goikolea, Caterina M. Bonnin, Ines Martin, Laura Salo, Ana Romaguera, Elena Rodriguez-Cano, Adriane R. Rosa, Eduard Vieta, Edith Pomarol-Clotet
Summary: This study aimed to assess the brain functional correlates of psychosocial functioning in individuals with bipolar disorder during a working memory task. The results revealed differences in brain activation between bipolar patients and healthy controls, particularly in the medial frontal cortex. In addition, the study found inverse correlations between psychosocial functioning and brain activation in several cortical regions, including the frontal, parietal, and temporo-occipital regions.
PSYCHIATRY RESEARCH
(2023)
Editorial Material
Psychiatry
Eduard Vieta
Article
Psychology, Clinical
Adrian I. Campos, Laura S. Van Velzen, Dick J. Veltman, Elena Pozzi, Sonia Ambrogi, Elizabeth D. Ballard, Nerisa Banaj, Zeynep Basgoeze, Sophie Bellow, Francesco Benedetti, Irene Bollettini, Katharina Brosch, Erick J. Canales-Rodriguez, Emily K. Clarke-Rubright, Lejla Colic, Colm G. Connolly, Philippe Courtet, Kathryn R. Cullen, Udo Dannlowski, Maria R. Dauvermann, Christopher G. Davey, Jeremy Deverdun, Katharina Dohm, Tracy Erwin-Grabner, Roberto Goya-Maldonado, Negar Fani, Lydia Fortea, Paola Fuentes-Claramonte, Ali Saffet Gonul, Ian H. Gotlib, Dominik Grotegerd, Mathew A. Harris, Ben J. Harrison, Courtney C. Haswell, Emma L. Hawkins, Dawson Hill, Yoshiyuki Hirano, Tiffany C. Ho, Fabrice Jollant, Tanja Jovanovic, Tilo Kircher, Bonnie Klimes-Dougan, Emmanuelle le Bars, Christine Lochner, Andrew M. McIntosh, Susanne Meinert, Yara Mekawi, Elisa Melloni, Philip Mitchell, Rajendra A. Morey, Akiko Nakagawa, Igor Nenadic, Emilie Olie, Fabricio Pereira, Rachel D. Phillips, Fabrizio Piras, Sara Poletti, Edith Pomarol-Clotet, Joaquim Radua, Kerry J. Ressler, Gloria Roberts, Elena Rodriguez-Cano, Matthew D. Sacchet, Raymond Salvador, Anca-Larisa Sandu, Eiji Shimizu, Aditya Singh, Gianfranco Spalletta, J. Douglas Steele, Dan J. Stein, Frederike Stein, Jennifer S. Stevens, Giana I. Teresi, Aslihan Uyar-Demir, Nic J. van der Wee, Steven J. van der Werff, Sanne J. H. van Rooij, Daniela Vecchio, Norma Verdolini, Eduard Vieta, Gordon D. Waiter, Heather Whalley, Sarah L. Whittle, Tony T. Yang, Carlos A. Zarate Jr, Paul M. Thompson, Neda Jahanshad, Anne-Laura van Harmelen, Hilary P. Blumberg, Lianne Schmaal, Miguel E. Renteria
Summary: A major limitation of current suicide research is the lack of power to identify robust correlates of suicidal thoughts or behavior. Variation in suicide risk assessment instruments used across cohorts may represent a limitation to pooling data in international consortia. Our findings suggest that multi-item instruments provide valuable information on different aspects of suicidal thoughts or behavior but share a modest core factor with single suicidal ideation items. Retrospective, multisite collaborations including distinct instruments should be feasible provided they harmonize across instruments or focus on specific constructs of suicidality.
Article
Psychiatry
Diego Hidalgo-Mazzei, Tim Mantingh, Xavier Perez de Mendiola, Ludovic Samalin, Juan Undurraga, Sergio Strejilevich, Emanuel Severus, Michael Bauer, Ana Gonzalez-Pinto, Willem A. Nolen, Allan H. Young, Eduard Vieta
Summary: A global survey conducted by the ISBD Task Force on the Role of Lithium in Bipolar Disorders revealed potential factors contributing to the decline in lithium prescriptions in the past two decades. The survey received 886 responses from 43 different countries, showing that lithium remains the preferred treatment option for bipolar disorder maintenance (59%), but negative beliefs, acute side effects, tolerability problems, and intoxication risk are reasons for not choosing lithium.
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS
(2023)
Review
Biochemistry & Molecular Biology
Sourav Khanra, Preethi Reddy, Anna Gimenez-Palomo, Chun Hui J. Park, Bruna Panizzutti, Madeleine McCallum, Shyam Sundar Arumugham, Shreekantiah Umesh, Monojit Debnath, Basudeb Das, Ganesan Venkatasubramanian, Melanie Ashton, Alyna Turner, Olivia M. Dean, Ken Walder, Eduard Vieta, Lakshmi N. Yatham, Isabella Pacchiarotti, Y. C. Janardhan Reddy, Nishant Goyal, Muralidharan Kesavan, Lluc Colomer, Michael Berk, Jee Hyun Kim
Summary: The core feature of bipolar disorder is pathological disturbances in mood, along with disrupted thinking and behavior. Due to its complex and heterogeneous etiology, a range of genetic and environmental factors are involved. This complexity and poorly understood neurobiology make it challenging to develop drugs, resulting in limited treatment options, especially for bipolar depression. Therefore, novel approaches are needed, such as investigating the potential of trimetazidine as a treatment option for bipolar depression.
MOLECULAR PSYCHIATRY
(2023)
Review
Neurosciences
Alessandro Serretti
Summary: Anhedonia is a core symptom of depression and other psychiatric disorders, referring to a lack of pleasure or reward. It is not only a psychological distress but also encompasses a range of reward processing deficits. Anhedonia is a relevant risk factor for suicidal behaviors and may operate independently of the severity of depressive episodes. It has also been associated with inflammation, which can have a reciprocal detrimental effect on depression. The neurophysiological bases of anhedonia mainly involve changes in striatal and prefrontal areas, with dopamine playing a key role as the neurotransmitter involved. Anhedonia is believed to have a significant genetic component and polygenic risk scores may be a tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants have shown limited benefit in treating anhedonia, also considering their potential to worsen anhedonia in some individuals. Other treatments such as agomelatine, vortioxetine, ketamine, and transcranial magnetic stimulation may be more effective. Psychotherapy, particularly cognitive-behavioral therapy and behavioral activation, is widely supported as beneficial for anhedonia. In conclusion, evidence suggests that anhedonia is partially independent from depression and requires careful evaluation and targeted treatment.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2023)